{
  "symbol": "RXRX",
  "company": "Recursion Pharmaceuticals, Inc.",
  "generated_at": "2026-06-24T07:36:52.178Z",
  "event_count": 4,
  "events": [
    {
      "type": "scout_dossier",
      "ts": "2026-06-20T14:50:06.686Z",
      "summary": "Recursion is an AI-native clinical-stage TechBio company with $654M cash and ~$72M debt. The stock has collapsed from its 52-week high of $7.18 to $3.23 (-55%), driven by collapsing revenue (Q1 2026: $6.5M vs $14.8M Q1 2025), accelerating cash burn (~320M/yr operating loss), and no meaningful insider buying. The only bullish signal is an analyst consensus target of $6.64 implying 106% upside, but that target was set before the Q2 revenue deterioration became evident. All recent insider activity (25 Form 4s reviewed) consists exclusively of: (1) pre-planned 10b5-1 sales by directors Borgeson ($110K), Bumpus ($15.5K), and Gibson (~$145K via conversions + sales); and (2) tax withholding surrenders on RSUs for CEO Khan and CFO Taylor — no discretionary open-market purchases of any kind from any officer or director. The June 4 AI pipeline update drove a 16% one-day spike that subsequently faded, suggesting limited sustained conviction. Next earnings Aug 5, 2026 is the primary near-term catalyst.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 28,
      "walltime_min": 23,
      "debug_path": "dossiers/2026-06-20-RXRX.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-13T19:11:12.785Z",
      "summary": "Recursion Pharmaceuticals is a clinical-stage AI-driven TechBio company with five programs in the clinic and >$500M received from pharma partnerships (Roche/Genentech, Sanofi). The investigation was triggered by a Form 4 cluster — however, upon reading every filing directly, ALL recent transactions are AUTOMATED SELLING under pre-established Rule 10b5-1 plans or RSU tax withholding. CEO Najat Khan sold $84K via 10b5-1; co-founder Blake Borgeson (director) sold ~$110K; director Namandje Bumpus sold ~$15.5K — all at market prices during a -25% YTD decline to near 52-week lows. There are zero open-market purchases from any insider in the past 90 days. The stock has negative forward P/E, no approved products, and revenue fell 56% YoY in FY2025 before recovering slightly Q1 2026. REC-4881 achieved Phase 2 success in FAP with FDA engagement ongoing — a genuine catalyst — but cash burn remains substantial (~$128M operating loss in Q1 alone) and the company is burning ~$300M+ annually against $655M of cash. The Form 4 cluster that triggered this investigation was entirely selling, not accumulation.",
      "verdict": "no_anomaly",
      "confidence": 5,
      "tool_calls": 28,
      "walltime_min": 21,
      "debug_path": "dossiers/2026-06-13-RXRX.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-06T21:56:10.716Z",
      "summary": "{\"symbol\":\"RXRX\",\"company\":\"Recursion Pharmaceuticals, Inc.\",\"investigation_summary\":\"Recursion is a clinical-stage TechBio company that has decoded biology at scale using AI for drug discovery. The company achieved its first Phase 2 success with REC-4881 in familial adenomatous polyposis (FAP) — a disease with no approved pharmacotherapies — and has active FDA engagement on a potential registrati",
      "verdict": "unparseable",
      "tool_calls": 21,
      "walltime_min": 27,
      "debug_path": "dossiers/2026-06-06-RXRX.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-05T03:59:48.359Z",
      "summary": "The Form 4 cluster that triggered this investigation resolves to pre-planned sales (10b5-1) and tax withholding events — not open-market conviction purchases. No insider bought shares in the past 90 days. The stock has collapsed ~47% from its 52-week high ($7.18 → $3.80), hit a new 52-week low in May 2026, and is now bouncing on positive clinical updates for REC-1245 and Phase 2 success with REC-4881 (FAP). Cash runway extends to early 2028 at current burn. The company participates at Goldman Sachs Healthcare Conference June 9 — an event catalyst exists within the window. However, without any genuine open-market insider buys, the smart-money signal is neutral-to-slightly negative given coordinated selling via 10b5-1 plans.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 21,
      "walltime_min": 18,
      "debug_path": "dossiers/2026-06-05-RXRX.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "RXRX",
    "call": "SELL",
    "confidence": 5,
    "score": -9,
    "factors": {
      "below_200dma": "-2",
      "below_50dma": "-1",
      "momentum_strong_down": "-2 (-40.4%)",
      "rsi_neutral": "0 (46.9)",
      "recent_macd_bearish_cross": "-2 (8d ago)",
      "broken_below_high": "-2 (-53.5% from high)"
    },
    "summary": "SELL (score -9) · 12-1 mom -40.4% · RSI 46.9 · below_both · -53.5% from high",
    "last_close": 3.16,
    "one_month_ago_close": 3.11,
    "twelve_month_ago_close": 5.22,
    "twelve_one_momentum_pct": -40.42,
    "rsi_14": 46.9,
    "ma_stack": "below_both",
    "from_period_high_pct": -53.46,
    "period_high": 6.79,
    "price_targets": {
      "bear": 3,
      "fair": 4.38,
      "bull": 10,
      "bear_return_pct": -5.1,
      "fair_return_pct": 38.5,
      "bull_return_pct": 216.5,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 3,
        "target_mean": 6.64286,
        "target_high": 10,
        "analyst_count": 7
      }
    },
    "generated_at": "2026-06-24T07:36:52.174Z"
  }
}